Novel synthesis route improves yield of alectinib in non-small cell lung cancer treatment, highlighting key cross-coupling steps.
A new synthetic route for the synthesis of Alectinib, which is used as an adjuvant and first line of treatment in ALK-positive non-small cell lung cancer, is reported. The developed route starts from readily available starting materials (4-(4-methoxyphenyl)butyric acid or 2-ethyl anisole) and employs Suzuki-Miyaura cross-coupling and reductive cyclization as key steps. Good yield and no regioisomeric mixture formation are the key highlights of this route.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: